ClinicalTrialsFinder
RecruitingPhase 1NCT04271488

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

An Open-label Parallel-Group Study to Evaluate Pharmacokinetics of E7090 and Its Metabolite in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

Sponsor

Eisai Co., Ltd.

Enrollment

18 participants

Start Date

Feb 27, 2020

Study Type

INTERVENTIONAL

Conditions

Hepatic Impairment

Summary

The primary purpose of the study is to evaluate the effects of mild and moderate hepatic impairment on PK of tasurgratinib after a single dose administration.

Eligibility

Min Age: 20 YearsMax Age: 79 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Tasurgratinib and a drug called Tasurgratinib for people with hepatic impairment. The study is currently recruiting participants at 8 locations. People eligible for this study include aged 20 Years to 79 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTasurgratinib

Tasurgratinib oral tablet.

DRUGTasurgratinib

Tasurgratinib oral capsule.

Locations(8)

Eisai Trial Site #6

Hakata, Fukuoka, Japan

Eisai Trial Site #4

Kurume, Fukuoka, Japan

Eisai Trial Site #2

Yuhu, Oita Prefecture, Japan

Eisai Trial Site #3

Bukyo-ku, Tokyo, Japan

Eisai Trial Site #1

Mintato-ku, Tokyo, Japan

Eisai Trial Site #8

Shinjuku-ku, Tokyo, Japan

Eisai Trial Site #5

Kofu, Yamanashi, Japan

Eisai Trial Site #7

Kyoto, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04271488

Related Trials

A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib

NCT071441114 locations

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

NCT050454821 location

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

NCT07643155

A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems

NCT070233543 locations

Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function

NCT07751250